Background: Gabapentin (GBP)-induced movement disorders (MDs) are under-recognized
adverse drug reactions. They are commonly not discussed with patients, and their sudden …

Drug-induced movement disorders affect a significant percentage of individuals, and they
are commonly overlooked and underdiagnosed in clinical practice. Many comorbidities can …

Neuroimaging can provide significant benefits in evaluating patients with movement
disorders associated with drugs. This literature review describes neuroimaging techniques …

The usual adverse events of amantadine are dizziness, dry mouth, and peripheral edema.
Postmarketing experience has revealed abnormal movements such as tremors, involuntary …

Movement disorders can be associated with various drugs and systemic diseases, posing
diagnostic challenges for clinicians. This review explores the spectrum of movement …

This review investigates the perplexing medical condition termed Fluoroquinolone-
Associated Disability (FQAD), a post-antibiotic therapy syndrome following the …

Secondary movement disorders (SMDs) represent a heterogeneous group of neurological
conditions characterized by abnormal, involuntary movements resulting from various …

Movement disorders encompass a diverse group of neurological conditions characterized
by abnormal voluntary or involuntary movements. These disorders can be classified broadly …

The usual adverse events of amantadine are dizziness, dry mouth, and peripheral edema.
Postmarketing experience has revealed abnormal movements such as tremors, involuntary …